A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals

Trial Profile

A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Denosumab (Primary) ; Risedronic acid
  • Indications Corticosteroid-induced osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms GIOP
  • Sponsors Amgen
  • Most Recent Events

    • 16 Jun 2018 Results of the final 24-month analysis, presented at the 19th Annual Congress of the European League Against Rheumatism
    • 08 Jun 2018 According to an Amgen media release,based on the results from this trial European Commission (EC) has approved a new indication for Prolia (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
    • 08 Jun 2018 Results published in the Amgen Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top